CARGO THERAPEUTICS INC(NASDAQ:CRGX) stock Fundamental Analysis

Fundamental Rating

CRGX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CRGX as it has an excellent financial health rating, but there are worries on the profitability. CRGX is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

CRGX had negative earnings in the past year.

CRGX had a negative operating cash flow in the past year.

1.2 Ratios

CRGX has a better Return On Assets (-34.18%) than 62.86% of its industry peers.

CRGX has a better Return On Equity (-38.45%) than 72.50% of its industry peers.

		Industry Rank	Sector Rank
ROA	-34.18%
ROE	-38.45%
ROIC	N/A

ROA(3y)-183.86%

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRGX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, CRGX has more shares outstanding

There is no outstanding debt for CRGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of 1.02, we must say that CRGX is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of CRGX (1.02) is better than 67.32% of its industry peers.

There is no outstanding debt for CRGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	1.02

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 18.95 indicates that CRGX has no problem at all paying its short term obligations.

With an excellent Current ratio value of 18.95, CRGX belongs to the best of the industry, outperforming 94.11% of the companies in the same industry.

CRGX has a Quick Ratio of 18.95. This indicates that CRGX is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of CRGX (18.95) is better than 94.11% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	18.95
Quick Ratio	18.95

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for CRGX have decreased strongly by -124.71% in the last year.

EPS 1Y (TTM)-124.71%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%98.14%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CRGX will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.13% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y83.34%

EPS Next 2Y37.63%

EPS Next 3Y23.78%

EPS Next 5Y14.13%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

CRGX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRGX. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

CRGX's earnings are expected to grow with 23.78% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y37.63%

EPS Next 3Y23.78%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for CRGX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CARGO THERAPEUTICS INC

NASDAQ:CRGX (2/28/2025, 8:00:00 PM)

After market: 3.79 +0.03 (+0.8%)

3.76

+0.12 (+3.3%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-12 2024-11-12/amc

Earnings (Next)03-21 2025-03-21/amc

Inst Owners113.88%

Inst Owner Change15.61%

Ins Owners0.24%

Ins Owner Change0%

Market Cap173.07M

Analysts52.86

Price Target12.92 (243.62%)

Short Float %10.75%

Short Ratio4.23

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)13.19%

Min EPS beat(2)2.64%

Max EPS beat(2)23.75%

EPS beat(4)3

Avg EPS beat(4)11.05%

Min EPS beat(4)-1.21%

Max EPS beat(4)23.75%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-60.24%

PT rev (3m)-59.79%

EPS NQ rev (1m)2.37%

EPS NQ rev (3m)4.6%

EPS NY rev (1m)0.68%

EPS NY rev (3m)1.57%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	0.43
P/tB	0.43
EV/EBITDA	N/A

EPS(TTM)-4.26

EYN/A

EPS(NY)-2.43

Fwd EYN/A

FCF(TTM)-3.05

FCFYN/A

OCF(TTM)-2.91

OCFYN/A

SpS0

BVpS8.71

TBVpS8.71

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-34.18%
ROE	-38.45%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-183.86%

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	267.3%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	18.95
Quick Ratio	18.95
Altman-Z	1.02

F-Score6

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)1145.04%

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-124.71%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%98.14%

EPS Next Y83.34%

EPS Next 2Y37.63%

EPS Next 3Y23.78%

EPS Next 5Y14.13%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-178.14%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-64.74%

EBIT Next 3Y8.82%

EBIT Next 5YN/A

FCF growth 1Y-181.35%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-179.2%

OCF growth 3YN/A

OCF growth 5YN/A

CARGO THERAPEUTICS INC (CRGX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens